Venture capital (VC) funding into Clinical Decision Support software companies doubled to $1.1 billion in the First Half (1H) of 2021, compared to $545 million in 1H 2020, according to the latest Mercom Digital Health Funding and M&A Report.
Clinical Decision Support software companies have raised nearly $6 billion since 2010, according to Mercom data.
Top funded Clinical Decision Support companies in 1H 2021:
PathAI, a provider of AI-powered clinical decision support tools for pathology laboratories, announced the closing of its $165 million Series C financing round. The financing round was co-led by D1 Capital Partners and Kaiser Permanente. Additional investors included General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, and LabCorp. PathAI has raised over $250 million to date, including the latest funding round.
WuXi Diagnostic, Shanghai-based precision medicine and clinical decision support software company, raised $150 million in a Series B funding round led by Thermo Fisher Scientific, Shiyu Capital, ABC International, Sunland Capital, CCBI Tech Venture, and YF Capital.
Strive Health, a kidney care decision-making platform, secured a $140 million Series B round of funding led by CapitalG, Alphabet’s independent growth fund. Redpoint, New Enterprise Associates (NEA), Town Hall Ventures, Ascension Ventures, and Echo Ventures participated in the funding round. Including the latest funding round, Strive Health has raised $223.5 million to date.
C2i Genomics, a provider of AI-powered genome cancer treatment intelligence and precision medicine platform, raised $100 million in a Series B round led by Casdin Capital, NFX, Duquesne Family Office, Section 32, iGlobe Partners, and Driehaus Capital. Additional investors include The Mark Foundation for Cancer Research, Silver Lake, Alexandria Real Estate, Gordon Asset Management, and LionBird.
Paige, a New York-based provider of computational pathology for diagnosing and treating cancer, raised $100 million in a Series C financing round. The company, founded in 2018, has raised over $195 million to date, including a $15 million Series B funding in 2020 from Goldman Sachs Merchant Banking Division.
